Update on Emerging HAE Therapies – Module 2

Module 2

0.50 CE Credit(s)
Expires: September 30, 2025


This activity is designed to meet the educational needs of clinicians involved in the diagnosis and management of patients with hereditary angioedema (HAE).


Upon completion of this activity, participants should be better able to:

  • Identify established and rational therapeutic targets for hereditary angioedema (HAE) therapy based on current understanding of HAE pathophysiology
  • Assess potential benefits and risks of emerging HAE therapeutic approaches aimed at reducing burden of disease
  • Evaluate available safety and efficacy clinical trial data on investigational HAE treatments


Jointly provided by RMEI Medical Education, LLC and the US Hereditary Angioedema Association. Funding provided by the US Hereditary Angioedema Association. No commercial support is provided for this accredited continuing education activity.


In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and the US Hereditary Angioedema Association. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.050 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-9999-23-013-H01-P)
Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).


To receive credit, participants must review the activity content and successfully complete the evaluation to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

There is no fee to participate.


Marc A. Riedl, MD, MS Professor, Medicine
Clinical Director, US HAEA Angioedema Center
Clinical Service Chief and Training Program Director
Division of Rheumatology, Allergy & Immunology
University of California, San Diego
San Diego, CA


RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Marc A. Riedl, MD, MS, has relevant financial relationships with Astria, BioCryst Pharmaceuticals, BioMarin Pharmaceuticals Inc., CSL Behring, Cycle Pharmaceuticals Ltd, Grifols S.A, Intellia Therapeutics, Inc., Ipsen, KalVista Pharma, Ono Pharmaceutical Co., Ltd, Pfizer, Pharming Group N.V, Pharvaris, REGENXBIO Inc., Sanofi/Regeneron, Spark, Takeda (Consultant); BioCryst Pharmaceuticals, BioMarin Pharmaceuticals Inc., CSL Behring, Ionis Pharmaceuticals, Inc., KalVista Pharma, Pharvaris, Takeda (Grant/Research Support); Grifols S.A, Pharming Group N.V, Takeda (Speaker/Speakers’ Bureau).

All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies.

Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

If you are a physician
treating a patient with HAE
and are interested in joining
our physician database,
please click here.
Connect Banner